{"schema_version":"secwatch.filing_event.v1","accession":"0000200406-24-000048","form_type":"8-K","ticker":"JNJ","cik":"0000200406","company_name":"JOHNSON & JOHNSON","filed_at":"2024-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.397482+00:00","generated_at":"2026-06-03T03:18:58.163389+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"JNJ proposes $6.475B talc settlement plan; Q1 GAAP EPS cut to $1.34","bullets":["Proposed plan pays $6.475B present value ($8.4B nominal over 25 years) to resolve all ovarian cancer cosmetic talc claims.","Incremental $2.7B charge; total talc reserve now ~$11B present value ($13.7B nominal) as of Q1 2024.","Previously reported GAAP net earnings reduced from $5.4B to $3.3B; EPS from $2.20 to $1.34 for Q1 2024.","Q1 2024 adjusted EPS of $2.71 unchanged; sales $21.38B (+2.3% YoY).","No impact to mesothelioma, state consumer claims; plan excludes those categories."],"urls":{"canonical":"https://secwatch.observer/filing/0000200406-24-000048","json":"https://secwatch.observer/filing/0000200406-24-000048.json","markdown":"https://secwatch.observer/filing/0000200406-24-000048.md","text":"https://secwatch.observer/filing/0000200406-24-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/200406/000020040624000048/0000200406-24-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/200406/000020040624000048/jnj-20240501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T03:18:58.163389+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d96ba5b7e22bcabdcb5e75eb42e6e95a2fed03be","claim":"JOHNSON & JOHNSON reported first quarter ended March 31, 2024 results: revenue $21,383, net income $3,255, EPS $1.34.","evidence_excerpt":"(Unaudited; in Millions Except Per Share Figures) FIRST QUARTER 2024 2023 Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) Sales to customers $ 21,383 100.0 $ 20,894 100.0 2.3 Cost of products sold 6,511 30.4 6,687 32.0 (2.6) Gross Profit 14,872 69.6 14,207 68.0 4.7 Selling, marketing and administrative expenses 5,257 24.6 4,906","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/200406/000020040624000048/0000200406-24-000048-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$21,383"},{"label":"Net income","value":"$3,255"},{"label":"EPS","value":"$1.34"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}